利拉鲁肽对2型糖尿病合并骨量异常患者CA19-9、CA724、CEA及SF的影响

doi:10.3969/j.issn.1671-7171.2018.03.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effects of liraglutide on levels of CA19-9 (carbohydrate antigen 19-9), CA724 (carbohydrate antigen 724), CEA (carcinoembryonic antigen) and serum ferritin (SF) in patients with type 2 diabetes mellitus patients with abnormal bone mass.【Methods】A total of 182 patients with type 2 diabetes combined with bone abnormalities and who received treatment in the Department of Endocrinology in our hospital from December 2015 to March 2017 were randomly divided into the observation group and the control group, with 91 cases in each group. Patients of two groups of were given dietary adjustments, exercise intervention and insulin glargine intensive treatment. According to blood glucose levels, patients in the control group received metformin treatment and patients in the observation group received liraglutide treatment. Both groups were treated for at least 3 months. The fasting blood glucose (FPG), 2 hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c) and fasting insulin (FINS) levels before and after treatment were compared between the two groups of patients. Meanwhile, the changes in tumor markers and SF levels before and after treatment were compared between the two groups as well.【Results】Before treatment, there was no significant difference in FPG, 2hPG, HbA1c, and FINS levels between the two groups (P>0.05). After treatment, the FPG, 2hPG, HbA1c, and FINS levels in the two groups of patients were significantly lower. The levels of 2hPG and FINS in the observation group were significantly lower than those of the control group; the difference were with statistically significant (P<0.05). Levels of CA19-9, CA724, CEA and SF showed no significant differences before treatment (P>0.05). However, after treatment, they were significantly decreased in both groups. CA19-9, CA724, CEA and SF levels in the observation group after treatment were significantly lower than those of the control group. The differences were statistically significant (P<0.05).【Conclusion】Liraglutide can effectively reduce blood glucose levels and improve insulin sensitivity in patients with type 2 diabetes mellitus complicated with abnormal bone mass. It can significantly reduce the levels of CA19-9, CA724, CEA and SF as well. Thus, it may reduce the risk of diabetic complications and occurrence of malignant tumor.

Key words： Diabetes Mellitus, Type 2/CO Bone Density Glucagon-Like Peptide 1/AA Hypoglycemic Agents/PD CA-19-9 Antigen/DE Carcinoembryonic Antigen/DE

Received: 15 January 2018

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Hai-xia
	WU Hui-ling
	WANG Xin-min
	et al

Cite this article:

ZHAO Hai-xia,WU Hui-ling,WANG Xin-min, et al. Effects of Liraglutide on CA19-9, CA724, CEA and SF in Type 2 Diabetic Patients with Bone Abnormalities[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(3): 428-431.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.03.004 OR http://www.jcr.net.cn/EN/Y2018/V35/I3/428

[1] 王鹏,周延民,于维先.糖尿病患者骨密度变化的相关因素研究进展[J].中国实验诊断学,2014,18(3):506-509.
[2] 王玉楠,许琳,吴瑶强,等.2型糖尿病患者合并骨量减少及骨质疏松症相关影响因素分析[J].中国骨质疏松杂志,2017,23(8):1045-1048.
[3] 陈晶波,黄勤.糖尿病与肿瘤标志物[J].中国糖尿病杂志,2016,24(2):166-168.
[4] 王晶,刘哲.2型糖尿病及其并发症患者中血清铁蛋白的变化及临床意义[J].陕西医学杂志,2016,45(1):106-109.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):447-498.
[6] 张智海,刘忠厚,李娜.中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.
[7] 叶景虹,钱梦华,姚文.2型糖尿病并发恶性肿瘤的流行病学特征[J].中国糖尿病杂志,2016,8(5):309-312.
[8] 吴胜利,潘巧云,吴克雄,等.糖尿病与恶性肿瘤相关性的作用机制研究[J].转化医学电子杂志,2016,3(4):14-16.
[9] 蒋斌,沈山梅,金露,等.2型糖尿病患者肿瘤标志物水平及其影响因素研究[J].中国全科医学,2017,20(32):3983-3990.
[10] 董庆莲.2型糖尿病患者血清糖类抗原19-9与血糖水平的相关性研究[J].临床内科杂志,2015,32(6):405-406.
[11] 徐媛媛,赵洪,张宇,等.老年2型糖尿病患者5种血清肿瘤标志物的表达及影响因素分析[J].上海交通大学学报(医学版),2016,36(7):1044-1048.
[12] Yong JC,Chung YS.Type 2 diabetes mellitus and bone fragility:Special focus on bone imaging[J].Osteoporosis & Sarcopenia,2016,2(1):20-24.
[13] Dankner R,Boffetta P,Balicer R D,et al.Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults[J].Am J Epidemiol,2016,183(12):1098-1106.
[14] 李彩艳,林凤平,赵辛元,等.血清铁蛋白与2型糖尿病的关系探讨[J].中国临床保健杂志,2016,19(4):354-356.
[15] 谭春萍,李毅,赵广,等.2型糖尿病患者铁代谢的相关性研究[J].医学综述,2014,20(8):1512-1514.
[16] 王艳妮,李转霞.二甲双胍联合利拉鲁肽对2型糖尿病合并非酒精性脂肪肝患者胰岛β细胞功能、肝功能及外周血Treg细胞的影响[J].医学临床研究,2018,35(1):11-14.
[17] Díez R,Madero M,Gamba G,et al.Renal AA amyloidosis in patients with type 2 diabetes mellitus[J].Nephron Extra,2014,4(2):119-126.
[18] 王红,张斯亮,关海霞.胰高糖素样肽-1受体激动剂对人甲状腺髓样癌细胞生长和能量代谢的影响[J].中国癌症杂志,2016,26(6):487-491.
[19] 郭锐,刘睿,关海霞.胰高糖素样肽-1受体激动剂对甲状腺髓样癌细胞生长和增殖的影响[J].解放军医药杂志,2016,28(7):43-46.
[20] 刘帼静,呼晓雷,何发忠,等.2型糖尿病骨质疏松研究进展[J].中国药理学通报,2016,32(10):1333-1336.
[21] 熊雪松,余显霞.2型糖尿病与骨质疏松症相关性研究进展[J].中国骨质疏松杂志,2017,23(1):130-135.
[22] 赵丽颖,李军,李思源,等.血清肿瘤标志物在 2 型糖尿病合并骨量异常患者中意义的研究[J].中国骨质疏松杂志,2017,23(12):1569-1573.
[23] 张广吾,申小英,王峰.二甲双胍对2型糖尿病患者血清癌胚抗原和糖类抗原19-9的影响[J].中华全科医学,2015,13(1):62-64.
[24] Akram KA,Tofighiyan T,Rakhshani MH.Effects of synbiotics on inflammatory markers in patients with type 2 diabetes mellitus[J].Glob J Health Sci,2015,7(7):1-5.